Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Geomicrobiological testing
Reexamination Certificate
2005-08-02
2005-08-02
Swartz, Rodney P. (Department: 1645)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Geomicrobiological testing
C435S009000, C435S184000, C435S185000, C435S192000, C435S200000, C435S234000, C435S248000, C435S320100
Reexamination Certificate
active
06924118
ABSTRACT:
Immunogenic compositions comprising recombinant attenuated intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens are provided. Exemplary immunogenic compositions include, but are not limited to attenuated recombinantMycobacteriaexpressing the major extracellular non-fusion proteins ofMycobacteriaand/or other intracellular pathogens. Other embodiments are provided wherein the recombinant attenuated intracellular pathogen is auxotrophic.
REFERENCES:
patent: 5504005 (1996-04-01), Bloom et al.
patent: 5583038 (1996-12-01), Stover
patent: 5591632 (1997-01-01), O'Donnell et al.
patent: 5679515 (1997-10-01), Stover et al.
patent: 5700683 (1997-12-01), Stover et al.
patent: 5736367 (1998-04-01), Haun et al.
patent: 5776465 (1998-07-01), O'Donnell et al.
patent: 5807723 (1998-09-01), Aldovini et al.
patent: 5830475 (1998-11-01), Aldovini et al.
patent: 5854055 (1998-12-01), Bloom et al.
patent: 5866403 (1999-02-01), Aldovini et al.
patent: 5869057 (1999-02-01), Rock
patent: 6015696 (2000-01-01), Yamada et al.
patent: WO 88/06626 (1988-09-01), None
patent: PCT/US03/30994 (2004-05-01), None
Cirillo et al., “Bacterial Vaccine Vectors and Bacillus Calmette-Guerin,” Clinical Infectious Diseases, 20:1001-9 (1995).
Fuerst et al., “Development and Analysis of Recombinant BCG Vector Systems,” AIDS Research and Human Retroviruses, vol. 8 (1992).
Hanson, et al., “Efficacy and Safety of Live Recombinant BCG Vaccines,”Dev. Biol. Stand. Basel, Karger, 84:229-36 (1995).
Harth et al., “High-Level Hetrologous Expression and Secretion in Rapidly Growing Nonpathogenic Mycobacteria of Four Major Mycobacterium Tuberculosis Extracellular Proteins Considered to be Leading Vaccine Candidates and Drug Targets,” Infection and Immunity, 65:2321-8 (Jun. 1997).
Harth et al., “Novel Insights Into the Genetics, Biochemistry, and Immunocytochemistry of the 30-Kilodalton Major Extracellular Protein of Mycobacterium Tuberculosis,” Infection and Immunity 64:3038-47 (Aug. 1996).
Horwitz et al., “Recombinant Bacillus Calmette-Guerin (BCG) Vaccines Expressing the Mycobacterium Tuberculosis 20-kDa Major Secretory Protein Induce Greater Protective Immunity Against Tuberculosis Than Conventional BCG Vaccines in a Highly Susceptible Animal Model,” PNAS 97:13853-8 (Dec. 2000).
Langermann et al., “Protective Humoral Response Against Pneumococcal Infection in Mice Elicited by Recombinant Bacille Calmette-Guerin Vaccines Expressing Pneumococcal Surface Protein A,” J. Exp. Med., The Rockeffeller University Press, 180:2277-86 (Dec. 1994).
Langermann et al., “Systemic and Mucosal Immunity Induced by BCG Vector Expressing Outer-Surface Protein A ofBorrelia burgdorferi,” Nature, vol. 372 (Dec. 1994).
Lee et al., “T-Cell Epitope Mapping of the Three Most Abundant Extracellular Proteins of Mycobacterium Tuberculosis in Outbread Guinea Pigs,” Infection and Immunity, 67:2665-70 (May 1999).
Naito et al., “The Antigen 85 Complex Vaccine Against Experimental Mycobacterium Leprae Infection in Mice,” Vaccine 19:795-8 (2000).
Ohara et al., “Characterization of the Transcriptional Initiation Regions of Genes for the Major Secreted Protein Antigens 85C and MPB51 of Mycobacterium Bovis BCG,” Vaccine 19:1294-7 (2000).
Ohara et al., “Inhibition of Multiplication of Mycobacterium Laprae in Mouse Foot Pads by Recombinant Bacillus Catmette-Guerin (BCG),” Vaccine, 19:1294-7 (2000).
Stover et al., “New Use of BCG for Recombinant Vaccines,” Nature, vol. 351 (Jun. 1991).
Stover et al., “Protective Immunity Elicited by rBCG Vaccines,” Brown (ed) “Recombinant Vectors in Vaccine Development,” Dev. Biol. Stand., Basel, Karger, 82:163-70 (1994).
Stover et al., “Protective Immunity Elicited by Recombinant Bacille Calmette-Guerin (BCG) Expressing Outer Surface Protein A (OspA) Lipoprotein: A Candidate Lyme Disease Vaccine,” J. Exp. Med., The Rockefeller University Press, 178:197-209 (1993).
Stover et al., “Use of Recombinant BCG as a Vaccine Delivery Vehicle,” Advances in Experimental Medicine and Biology, vol. 327 (date).
Yasutomi et al., “Immunization with Recombinant BCG-SIV Elicits SIV-Specific Cytotoxic T. Lymphocytes in Rhesus Monkeys,” The Journal of Immunology, 150:3101-7 (Apr. 1993).
Harth Gunter
Horwitz Marcus A.
Tullius Michael V.
Cullman Louis C.
Glasky Michelle S.
Preston Gates & Ellis LLP
Swartz Rodney P.
The Regents of the University of California
LandOfFree
Recombinant intracellular pathogen immunogenic compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant intracellular pathogen immunogenic compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant intracellular pathogen immunogenic compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3492496